2013-04-23 top institute pharma spring meeting, utrecht
DESCRIPTION
TRANSCRIPT
Companion Diagnostics:an update
Prof. Alain van Gool
Netherlands Organisation for Applied Scientific Research (TNO)Radboud University Nijmegen Medical Centre
Radboud University Nijmegen
TI Pharma Spring Meeting
Utrecht, 23rd April 2013
Companion Diagnostics
Right drugin right patientat right doseat right time
In other words:Apply a well characterized therapy in a biological system you know well to treat a disease you understand well, in a way that you know works.
Use (molecular) biomarkers as diagnostic companions of a drug.
TI Pharma Spring meetingUtrecht, 23 April 2013
Alain van Gool
2
What type of biomarkers to use?
{Biomarkers definition working group, 2001 }
Definition: ‘a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention’
Or ‘Whatever works in adding value’
Molecular biomarkers provide a molecular impression of a biological system (cell, animal, human)
Biomarkers can be various sorts of data, or combinations thereof
3TI Pharma Spring meeting
Utrecht, 23 April 2013Alain van Gool
Companion Diagnostics – some numbers
At present in pharmaceutical development:40.000 clinical trials ongoing16.000 trials in oncology8.000 trials in oncology have a companion diagnostic
At present on market:113 Biomarker in drug label (2012; up from 69 in 2010 = +64%)
16 CDx testing needed (2012; up from 4 in 2010 = +400%)
Costs of development:>1.000 MUSD per drug
~10 MUSD per diagnostic
Source: www.fda.gov
TI Pharma Spring meetingUtrecht, 23 April 2013
Alain van Gool
4
Companion Diagnostics
Metabolism
Efficacy or safety
Source: www.fda.gov
TI Pharma Spring meetingUtrecht, 23 April 2013
Alain van Gool
5
Companion Diagnostics in Oncology
V600D/E
Kinase domain
{Roberts and Der, 2007}
B-RAFV600D/E mutation: constitutively active kinase, oncogenic addiction
Overactivate ERK pathway drives cell proliferation
RAF inhibitors block growth of tumor xenografts with B-RAFV600D/E mutation
Prevalence of B-RAFV600D/E
Melanoma (60%), colon (15%), ovarian (30%), thyroid (30%) cancer
Develop B-RAF inhibitors with B-RAFV600D/E as companion diagnostic
6TI Pharma Spring meeting
Utrecht, 23 April 2013Alain van Gool
7
Clinical efficacy of Vemurafenib (PLX-4032, Zelbora f)
Key biomarkers:
Stratification: BRAFV600E mutationMechanism: P-ERK
Cyclin-D1Efficacy: Ki-67
18FDG-PET, CTClinical endpoint: progression-free survival (%)
{Source: Flaherty et al, NEJM 2010}{Source: Chapman et al, NEJM 2011}
7
TI Pharma Spring meetingUtrecht, 23 April 2013
Alain van Gool
8
Clinical effects of Vemurafenib
{Wagle et al, 2011, J Clin Oncol 29:3085}
Before Rx Vemurafenib, 15 weeks Vemurafenib, 23 weeks
• Strong initial effects vemurafenib• Drug resistancy• Reccurence of tumors
8
TI Pharma Spring meetingUtrecht, 23 April 2013
Alain van Gool
EC DG for Research and InnovationAlain van Gool
Brussels, 11 Sept 2012
9
• BRAFV600D/E is considered the driving mutation
• However, varying levels of BRAFV600D/E mutation found in regions of a primary melanoma
• Molecular heterogeneity in diseased tissue
• Biomarker levels in tissue and body fluids will vary
• New biomarkers are needed
• Challenge for companion diagnostics
{Source: Yancovitz, PLoS One 2012}
Tumor tissue heterogeneity
TI Pharma Spring meetingUtrecht, 23 April 2013
Alain van Gool
The innovation gap in biomarker development
10
• Imbalance between biomarker discovery and application.
• Gap 1: Strong focus on discovery of new biomarkers, few biomarkers progress beyond initial publication to multi-center clinical validation.
• Gap 2: Insufficient demonstrated added value of new clinical biomarker and limited development of a commercially viable diagnostic biomarker test.
Discovery Clinical validation/confirmation
Diagnostictest
Number ofbiomarkers
Gap 1
Gap 2
TI Pharma Spring meetingUtrecht, 23 April 2013
Alain van Gool
11
EmergingDiscovery Clinical validation/
confirmation
Diagnosticapplication
Number ofbiomarkers
ExperimentalDiscovery
Assay kitdevelopment
Assay development
Early Late
– Many new biomarkers are panels (RNA, protein, biochemical, imaging)
– Not wise to discover yet an other biomarker
– Focus on selecting the best biomarker (panels) among those already found (scientific and patent literature, databases, etc)
– Develop those biomarkers tot clinically applicable tests
Imbalance between biomarker discovery and applicati on
<10 biomarkers
Eg prostate cancerMay 2011: 2,231 biomarkersNov 2012: 6,562 biomarkers{Source: Thomson Reuters Biomarkers Module}
11TI Pharma Spring meeting
Utrecht, 23 April 2013Alain van Gool
Biomarker innovation gap highlighted in topsector Life Sciences & Health
{www.rijksoverheid.nl}
{http://www.zonmw.nl/nl/roadmaps-lsh/}
Roadmap Molecular Diagnostics:
• Build an efficient biomarker development pipeline in Netherlands to enable fast
progress of biomarkers from discovery to clinical implementation
• Bring all stakeholders together in a functional open innovation network based on
public-private-partnerships
• Have end-users (patients, clinicians) direct biomarker development in beginning
9 TopSectors 11 Roadmaps in TopSector Life Sciences & Health
Topsectors: initiative of Netherlands government to re-define the interest and focus of industry in public-private partnerships (2012)
Uptake of new biomarkers in clinical careResearch/technology push:
Biomarkers can and should provide the molecular part of this healthcare model in monitoring and follow-up
Daily practice in clinical assessment: Combination of personal opinion (patient and physician), physical examination, clinical chemistry to generate personal profiles
New biomarkers are added where deemed useful by physician
Act accordingly in follow-up care (more or less personalized)Medication (a.o. personalized medicine)
Nutrition (a.o. individualized diets)
Life style (a.o. individualized exercise, counseling)
Slow uptake of new biomarkersLimited by careful / conservative attitude of clinicians (added value of new biomarker?)
Limited by reimbursement options by insurers (increasingly important)
13TI Pharma Spring meeting
Utrecht, 23 April 2013Alain van Gool
Personal profiles
Source: Barabási 2007 NEJM 357; 4}
• People are different• Different networks influences• Different risk factors
14TI Pharma Spring meeting
Utrecht, 23 April 2013Alain van Gool
BIODATA
PERSONALIZED
INTERVENTIONS
RISK FACTOR PATTERN
MOLECULAR LIFESTYLE / ENVIRONMENT
Metabolites RNA Protein
DNA Biochemical process
Enzymatic activity Imaging
mDNA Nutrition
Environment Social
network Attitude in life
Stress work / private
MULTIPARAMETER
PERSONAL PROFILES Statistics
Selection
Ranking
LIFESTYLE
NUTRITION
PHARMA
TI Pharma Spring meetingUtrecht, 23 April 2013
Alain van Gool
15
Example personal profile-based patient assessment
{Chen et al, Cell 2012, 148: 1293}
Concept:• Continuous monitoring (n=1)• Routine biomarkers to alert• Omics to explain• Early intervention
16TI Pharma Spring meeting
Utrecht, 23 April 2013Alain van Gool
From clinical Omics to personalized treatment:• 12 families with liver disease and dilated cardiomyopathy (5-20 years)• Initial clinical assessment didn’t yield clear cause of symptoms• Specific sugar loss of serum transferrin identified via glycoproteomics• Genetic defect in glycosylation enzyme identified via exome sequencing• Outcome: Explanation of disease• Outcome: Dietary intervention as succesful personalized therapy• Outcome: Glycoprofile being developed as diagnostic test by mass spectrometry
Example from rare diseases
Dietaryintervention
{Dirk Lefeber et al,submitted}
17
Incomplete glycosylation Complete glycosylation
TI Pharma Spring meetingUtrecht, 23 April 2013
Alain van Gool
EC DG for Research and InnovationAlain van Gool
Brussels, 11 Sept 2012
Oncology
CVD, neuro, immune
Diabetes
Personal profiles differ per disease phenotype
TI Pharma Spring meetingUtrecht, 23 April 2013
Alain van Gool
18
EC DG for Research and InnovationAlain van Gool
Brussels, 11 Sept 2012
• Obesity• Diabetes type 2
HEALTH DISEASE COMPLICATIONS
• Atherosclerosis• Nephropathy fibrosis• Osteoarthritis• Stroke• etc
Metabolic syndrome
metabolic disturbance local inflammation
Not a single cause but complex multifactorial diseasesDisturbed equilibrium between multiple pathways and key components
A system biology approach is neededFor discovery research, diagnosis and treatment
Continuous monitoring really pays offMost effective therapy is ‘eat better, move more’ (lifestyle change)
Nutriceuticals / Lifestyle Food
Pharma
19
TI Pharma Spring meetingUtrecht, 23 April 2013
Alain van Gool
EC DG for Research and InnovationAlain van Gool
Brussels, 11 Sept 2012
Each organ has its own characteristics in maintaining/loosing flexibility and this determines the health to diabetes transition.
{Nolan, Lancet 2011}
A sure need for system biology
High need to study the effect of drugs/nutrition on each of these organs and their interactionwithin the whole system of each person.
TI Pharma Spring meetingUtrecht, 23 April 2013
Alain van Gool
20
EC DG for Research and InnovationAlain van Gool
Brussels, 11 Sept 2012
21
Working in complex human biological systems requires a systems biology approach
Way forward:1. Focus on key processes2. Measure key node biomarkers3. Convert to a functional fingerprint assay panel4. Make actionable personalized decision on health / disease management5. Test added value in real life through field labs
EC DG for Research and InnovationAlain van Gool
Brussels, 11 Sept 2012
Important processes in T2D
Diagnosis Potential interventionsDietary/LS Pharma
1.Pancreatic β-cell function (impaired insulin secretion)
*OGTT: I/∆G and DI(0)*PYY, Arg, His, Phe, Val, Leu
Lifestyle; β-cell protective nutrients (MUFA/isoflavonoids);
β -cell protective medication (TZDs, GLP-1 analogs, DPP4-inhibitors)
2.Muscle insulin resistance (decreased glucose uptake)
*OGTT: Muscle insulin resistance index, Insulin secretion/insulin resistance index *Val, Ile, Leu, Gamma-glutamylderivates, Tyr, Phe, Met
PUFA/SFA balance; Physical activity; Weight loss;
TZDs (e.g.PPARγ)
3.Hepatic insulin resistance (decreased glucose uptake and increased hepatic glucose production-HGP)
*Hepatic insulin resistance index *OGTT: Hepatic insulin sensitivity index*ALAT, ASAT, bilirubine, GGT, ALP, ck-18 fragments, lactate, α-hydroxybutyrate, β-hydroxybutyrate
Decrease SFA and n-6 PUFA, and increase n-3 PUFA; Weight loss;
Metformin; TZDs; Exenatide (GLP-1 analog); DPP4 inhibitors
4. Adipocyte insulin resistance and lipotoxicity
*basal adipocyte insulin resistance index *FFA platform, glycerol
α-lipoic acid; PUFA/SFA balance; Omega 3 fatty acids; Chitosan/plantsterols;
TZDs; Acipimox
5. GI tract (incretin deficiency/resistance)
*ivGTT vs OGTT*GLP-1, GIP, glucagon, galzuren
MUFA; Dietary fibre (pasta/rye bread);
Exenatide
6. Pancreatic α-cell (hyperglucagonemia)
*fasting plasma glucagon ? Glucagon receptor antagonists; Exenatide; DPP4 inhibitors
7A.Chronic low-grade inflammation in pancreas, muscle, liver, adipose tissue, hypothalamus7B. Vascular inflammation
*CRP, total leucocytes* V-CAM, I-CAM, Oxylipids, cytokines
Fish oil/n-3 fatty acids; Vit. C/Vit. E/Carotenoids;
Salicylates; TNF-α inhibitors and others
TI Pharma Spring meetingUtrecht, 23 April 2013
Alain van Gool
22
EC DG for Research and InnovationAlain van Gool
Brussels, 11 Sept 2012
Field labs: test health care concepts in real life
• Build field lab with pre-diabetic patients, physicians, dietitians, insurers, etc
• Measure individual ‘risk’ parameters for metabolic syndrome +/- challenge• phenotypes, clinical chemistry, specific Omics, etc
• Convert data into a personal profile + personalized health advice• life style +/- nutrition +/- pharmaceutical drugs
• Test personalized health concept in field lab following P4 medicine principle
• Alliance “Expedition Sustainable Care, starting with diabetes”
TI Pharma Spring meetingUtrecht, 23 April 2013
Alain van Gool
23
EC DG for Research and InnovationAlain van Gool
Brussels, 11 Sept 2012
Oncology
CVD, neuro, immune
Diabetes
Personal profiles differ per disease phenotype
TI Pharma Spring meetingUtrecht, 23 April 2013
Alain van Gool
24
High attrition in most chronic diseases
{Source: Kola, 2008, Nature 83, 2: 227}
• Multifactorial causes of disease, mostly not well understood
• Risk factors include both molecular as lifestyle/environmental factors
• Treatment is often symptom-based, not mechanism-based
• System approach in diagnosis and treatment (systems medicine)
• Need improved disease definitions and understanding
25
TI Pharma Spring meetingUtrecht, 23 April 2013
Alain van Gool
EC DG for Research and InnovationAlain van Gool
Brussels, 11 Sept 2012
Redefining disease
{Nature Reviews Drug Discovery 2011, 10: 641}
26
8th IMI call:
Joined effort in EU to improve disease definitions and define best potential therapies
1. RA, SLE
2. AD, PD
TI Pharma Spring meetingUtrecht, 23 April 2013
Alain van Gool
EC DG for Research and InnovationAlain van Gool
Brussels, 11 Sept 2012
Human DiseasomesFrom Barabási 2007 NEJM 357:4
Redefining disease
27
TI Pharma Spring meetingUtrecht, 23 April 2013
Alain van Gool
EC DG for Research and InnovationAlain van Gool
Brussels, 11 Sept 2012
Redefining disease: Medicine 3.0
Concept:• Target causes of disease rather than
symptoms• Identify and quantify common
mechanisms of chronic diseases• Identify new targets for interventionNL: Proposal submitted (10 yrs, 30MEur)EU: Align with IMI and Horizon2020
28TI Pharma Spring meeting
Utrecht, 23 April 2013Alain van Gool
EC DG for Research and InnovationAlain van Gool
Brussels, 11 Sept 2012
Network medicine
Proposed procedure for network-based drug discovery for personalized therapy
Source: Schadt et al, 2009, Nature, 8:268}
29
TI Pharma Spring meetingUtrecht, 23 April 2013
Alain van Gool
Personalized Health = Food + Lifestyle + Pharma
30
TI Pharma Spring meetingUtrecht, 23 April 2013
Alain van Gool
Acknowledgements
Jan van der Greef
Ben van Ommen
Peter van Dijken
Robert Kleemann
Bas Kremer
Tom Rullmann
Suzan Wopereis
Marijana Radonjic
Thomas Kelder
and others
Ron Wevers
Jolein Gloerich
Dirk Lefeber
Monique Scherpenzeel
Udo Engelke
and others
Lutgarde Buydens
Jasper Engel
Lionel Blanchet
Jeroen Jansen
and others
Radboud UMC Personalized Medicine Taskforce:
Andrea Evers, Alain van Gool, Joris Veltman, Jan Kremer,
Maroeska Rovers, Jack Schalken, Bas Bloem, Gerdi Egberink,
Viola Peulen, Martijn Hoogboom, Martijn Gerretsen
31
TI Pharma Spring meetingUtrecht, 23 April 2013
Alain van Gool